Ken Griffin Milestone Pharmaceuticals Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	SELL	$1.4 - $2.2 $420 - $660	-300 Reduced 7.89%	3,500 $6,000
Q3 2023 Nov 14, 2023	SELL	$2.68 - $3.69 $6,164 - $8,487	-2,300 Reduced 37.7%	3,800 $11,000
Q2 2023 Aug 14, 2023	SELL	$2.85 - $4.4 $203,490 - $314,160	-71,400 Reduced 92.13%	6,100 $17,000
Q1 2023 May 15, 2023	BUY	$3.14 - $4.2 $217,288 - $290,640	69,200 Added 833.73%	77,500 $305,000
Q4 2022 Feb 14, 2023	SELL	$3.53 - $9.5 $390,065 - $1.05 Million	-110,500 Reduced 93.01%	8,300 $32,000
Q3 2022 Nov 14, 2022	BUY	$5.86 - $9.43 $485,208 - $780,804	82,800 Added 230.0%	118,800 $1.09 Million

28.7M

200

Ticker MIST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,010,900
Market Cap $54M
Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II cl...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.